Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model

Journal of Clinical Gastroenterology

Volumn 48, Issue , 2014, Pages S12-S17

  Del Carmen, Silvina ^a   Rosique, Rebeca Martín ^b,c   Saraiva, Tessália ^d   Zurita Turk, Meritxell ^d   Miyoshi, Anderson ^d   Azevedo, Vasco ^d   De Moreno De LeBlanc, Alejandra ^a   Langella, Philippe ^b,c   Bermúdez Humarán, Luis G ^b,c   LeBlanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b INRA   (France)

^c UMR1319 MICALIS   (France)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

DNA vaccine; inflammatory bowel diseases (IBD); Interleukin 10; Lactococcus lactis

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 10; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL STRAIN; BODY WEIGHT; CHRONIC DISEASE; COLITIS; COLON; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION SYSTEM; HOST CELL; INFLAMMATION; LACTOCOCCUS LACTIS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLASMID; PROTECTION; RECURRENT DISEASE; WEIGHT CHANGE; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMICALLY INDUCED; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; INTESTINE MUCOSA; LACTOBACILLUS; METABOLISM; MICROBIOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TIME;

ANIMALS; COLITIS; COLON; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTESTINAL MUCOSA; LACTOBACILLUS; MICE, INBRED BALB C; PROBIOTICS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRINITROBENZENESULFONIC ACID; WEIGHT LOSS;

EID: 84916601452     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000235     Document Type: Conference Paper

References (33)

1. Kuhbacher T, Folsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol. 2007;13:1149-1155.
2. Martin R, Miquel S, Ulmer J, et al. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. Microb Cell Fact. 2013;12:71. DOI: 10.1186/ 1475-2859-12-71.
3. FAO/WHO. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report, Cordoba, Argentina 2001; 1-4.
4. Bermudez-Humaran LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin. 2009;5: 264-267.
5. Bermudez-Humaran LG, Aubry C, Motta J-P, et al. Engineering lactococci and lactobacilli for human health. Curr Opin Microbiol. 2013;16:278-283.
6. LeBlanc JG, Aubry C, Cortes-Perez NG, et al. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett. 2013; 344:1-9.
7. Schotte L, Steidler L, Vandekerckhove J, et al. Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol. 2000;27:761-765.
8. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
9. de Moreno de LeBlanc A, del Carmen S, Zurita-Turk M, et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol. 2011;2011:1-11.
10. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
11. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotech. 2003; 21:785-789.
12. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754-759.
13. Steidler L, Robinson K, Chamberlain L, et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun. 1998;66:3183-3189.
14. Bermudez-Humaran LG, Corthier G, Langella P. recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res Dev Microbiol. 2004;8:147-160.
15. Benbouziane B, Ribelles P, Aubry C, et al. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol. 2013; 168:120-129.
16. Miyoshi A, Jamet E, Commissaire J, et al. A xylose inducible expression system for Lactococcus lactis. FEMS Microbiol Lett. 2004;239:205-212.
17. Pontes D, Azevedo M, Innocentin S, et al. Immune response elicited by DNA vaccination using Lactococcus lactis is modified by the production of surface exposed pathogenic protein. PLoS One. 2014;9:e84509.
18. Guimaraes VD, Innocentin S, Lefevre F, et al. Use of native lactococci as vehicles for delivery of DNA into mammalian epithelial cells. Appl Environ Microbiol. 2006;72:7091-7097.
19. Chatel JM, Pothelune L, Ah-Leung S, et al. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. Gene Ther. 2008;15:1184-1190.
20. Martin R, Chain F, Miquel S, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis. 2014;20:417-430.
21. Guimaraes V, Innocentin S, Chatel JM, et al. A new plasmid vector for DNA delivery using lactococci. Genet Vaccin Ther. 2009;7:4. DOI: 10.1186/1479-0556-7-4.
22. del Carmen S, Zurita-Turk M, Alvarenga Lima F, et al. A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. Eur J Inflamm. 2013;11:641-645.
23. Zurita-Turk M, del Carmen S, Santos ACG, et al. The use of an IL-10 DNA mucosal system delivered by Lactococcus lactis attenuates inflammation in a murine model induced by DSS. BMC Biotechnology. 2014;14. Doi:10.1186/1472-6750-14-73.
24. Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot. 2011; 74:801-811.
25. Bahey-El-Din M, Gahan CG. Lactococcus lactis: from the dairy industry to antigen and therapeutic protein delivery. Discov Med. 2010;9:455-461.
26. Marlow GJ, van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn's disease patients. World J Gastroenterol. 2013;19:3931-3941.
27. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472.
28. Rachmawati H, Beljaars L, Reker-Smit C, et al. Pharmacokinetic and biodistribution profile of recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm Res. 2004;21:2072-2078.
29. Bhavsar M, Amiji M. Oral IL-10 gene delivery in a microsphere- based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008;15: 1200-1209.
30. Wallace JL, Le T, Carter L, et al. Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods. 1995;33:237-239.
31. Pontes D, Innocentin S, del Carmen S, et al. Production of fibronectin binding protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo. PloS One. 2012;7:e44892.
32. Nouaille S, Ribeiro LA, Miyoshi A, et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res. 2003;2:102-111.
33. del Carmen S, de Moreno de LeBlanc A, Perdigon G, et al. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn's disease. J Mol Microbiol Biotechnol. 2012;21:138-146.